Analyst Ratings For bluebird bio Inc (NASDAQ:BLUE)
Today, JPMorgan Chase & Co. reiterated its Buy rating on bluebird bio Inc (NASDAQ:BLUE) with a price target of $195.00.
There are 11 Buy Ratings, 9 Hold Ratings, 1 Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on bluebird bio Inc (NASDAQ:BLUE) is Buy with a consensus target price of $168.8069 per share, a potential 43.71% upside.
Some recent analyst ratings include
- 6/13/2019-bluebird bio Inc (NASDAQ:BLUE) had its Buy rating reiterated by JPMorgan Chase & Co. with a $195.00 price target
- 5/15/2019-bluebird bio Inc (NASDAQ:BLUE) gets downgraded to Neutral by Wedbush with a price target of $131.00
- 5/3/2019-bluebird bio Inc (NASDAQ:BLUE) had its Buy rating reiterated by William Blair
- 3/5/2019-bluebird bio Inc (NASDAQ:BLUE) gets downgraded to Market Perform by Svb Leerink
- On 6/10/2019 Jeffrey T Walsh, Insider, sold 1,400 with an average share price of $125.44 per share and the total transaction amounting to $175,616.00.
- On 6/5/2019 Philip D Gregory, Insider, sold 1,800 with an average share price of $128.60 per share and the total transaction amounting to $231,480.00.
- On 5/10/2019 Jeffrey T Walsh, Insider, sold 1,500 with an average share price of $132.30 per share and the total transaction amounting to $198,450.00.
- On 5/6/2019 David Davidson, Insider, sold 6,360 with an average share price of $138.95 per share and the total transaction amounting to $883,722.00.
- On 4/10/2019 Jeffrey T Walsh, Insider, sold 1,500 with an average share price of $156.65 per share and the total transaction amounting to $234,975.00.
- On 4/4/2019 David Davidson, Insider, sold 6,360 with an average share price of $160.06 per share and the total transaction amounting to $1,017,981.60.
- On 3/13/2019 David Davidson, Insider, sold 3,101 with an average share price of $146.41 per share and the total transaction amounting to $454,017.41.
About bluebird bio Inc (NASDAQ:BLUE)
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder. Read More…
Recent Trading Activity for bluebird bio Inc (NASDAQ:BLUE)
Shares of bluebird bio Inc closed the previous trading session at 117.46 −1.00 0.84% with 113.47 shares trading hands.